EEG-vigilance and response to stimulants in paediatric patients with attention deficit/hyperactivity disorder

Clin Neurophysiol. 2010 Sep;121(9):1511-1518. doi: 10.1016/j.clinph.2010.03.021. Epub 2010 Apr 9.

Abstract

Objective: In a pilot study it was investigated whether assessment of EEG-vigilance is useful for the prediction of treatment outcome in ADHD patients.

Methods: Resting EEG recordings of 49 unmedicated ADHD patients and 49 age-matched controls were analyzed. Vigilance level was determined for 1-s segments with a computer-based algorithm, distinguishing six stages from higher vigilance stages A1, A2 and A3 with dominant alpha activity to lower stages B1 and B2/3 with low amplitude non-alpha and increasing theta and delta activity and further onto stage C characterizing sleep onset. Treatment outcome was measured as changes in continuous performance test (CPT) results from baseline after at least 4 weeks of medication.

Results: ADHD patients spend less time in higher A1-stages (ADHD=66%, controls=81%) and showed more switching between vigilance stages (ADHD=26.02%, controls=19.09%), indicating a more unstable vigilance regulation. Patients with less stable vigilance showed a worse pre-treatment CPT performance but achieved a better post-treatment result compared to patients with more stable vigilance regulation. These differences did not reach statistical significance.

Conclusions: Signs of vigilance instability where found in ADHD patients compared to controls. Those patients with a higher degree of vigilance instability seemed to benefit more from stimulant medication.

Significance: This is the first investigation of EEG-vigilance in ADHD-patients. Results are limited by a short recording time but the results strongly suggest further investigation of the vigilance regulation in ADHD patients.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adrenergic Uptake Inhibitors / pharmacology*
  • Adrenergic Uptake Inhibitors / therapeutic use
  • Analysis of Variance
  • Arousal / drug effects*
  • Arousal / physiology*
  • Atomoxetine Hydrochloride
  • Attention Deficit Disorder with Hyperactivity / drug therapy
  • Attention Deficit Disorder with Hyperactivity / physiopathology*
  • Case-Control Studies
  • Child
  • Electroencephalography / methods
  • Humans
  • Male
  • Neuropsychological Tests
  • Propylamines / pharmacology*
  • Propylamines / therapeutic use
  • Reaction Time / drug effects
  • Reaction Time / physiology
  • Time Factors

Substances

  • Adrenergic Uptake Inhibitors
  • Propylamines
  • Atomoxetine Hydrochloride